About Us
Pioneers Who Wrote the Book on
Targeted Protein Degradation
We created IMiDs
Our drug development team is responsible for creating one of the most successful classes of anti-cancer drugs globally, the IMiD franchise of compounds, launched by Celgene. IMiDs (small molecule, cereblon binding “molecular glues), are the only class of clinically-validated protein degrading compounds that are commercially available today.
We are leveraging the discovery of the E3 ligase Cereblon
The identification of cereblon as a key target of the IMiDs validated targeted protein degradation as a drug development strategy with vast commercial potential. We have leveraged our unmatched “molecular glue” experience with the IMiDs in designing the BioTheryX PHM franchise.
Our Protein Homeostatic Modulator PHM® Platform
A Powerful Drug Discovery Engine
Our principal technology platform centers on targeted protein degradation with our PHM® ‘molecular glues’, that enable the design of small molecules to regulate protein equilibrium. Molecular glues can be used to either create a complex of proteins that is more stable by attaching them, giving them better functionality by gluing a diseased protein to a “regulator” protein. This technology utilizes the body’s own protein disposal system to selectively degrade and remove disease-causing proteins. We believe our technology has the potential to address a broad range of disease targets, including those that have to date been considered undruggable.
“This platform is exciting and broad, and can be applied to any substrate. It opens a wide window to the development of novel therapeutic modalities to a broad array of diseases, including malignancies and neurodegenerative disorders.”
Professor Aaron Ciechanover
Nobel Laureate in Chemistry (2004) for the Discovery of Ubiquitin Mediated Protein Degradation
Our Portfolio of High Value Assets in Protein Modulation, Either Targeted Degradation or Regulation to Achieve Homeostasis, Includes:
